What Providers Need to Know about Monovalent COVID-19 Vaccines: Novavax

COVID-19 vaccines will be covered under Vaccines for Children

Product Overview

Neutralizing responses against XBB subvariants achieve levels comparable to homologous XBB.1.5 response
Consistent responses against all variants including emerging XBB subvariants
Only Protein based COVID19 vaccine in the US
Same dose/formulation/vial for all approved indications (0.5mL/dose) - Ready to use and refrigerator stable (no mixing, dilution or thawing)

Administration

Individuals previously vaccinated with any COVID-19 vaccine:
• one 0.5ml dose from the 5-dose multi vial of the Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) is administered at least 2 months after receipt of the last previous dose of an original monovalent (original) or bivalent (original and Omicron BA.4/BA.5) COVID-19 vaccine.

Individuals not previously vaccinated with any COVID-19 vaccine:
• two 0.5ml doses from the 5-dose multi vial of the Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) are administered three weeks apart.

Immunocompromised individuals:
• an additional 0.5ml dose of Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) may be administered at least 2 months following the last dose of a COVID-19 vaccine (2023-2024 Formula).

Additional doses of Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) may be administered at the discretion of the healthcare provider, taking into consideration the individual’s clinical circumstances. The timing of the additional doses may be based on the individual’s clinical circumstances.

Resources
• ACIP Presentation Sept 12 2023 (cdc.gov)
• Novavax COVID-19 Vaccine, Adjuvanted | FDA